REDHILL BIOPHARMA LTD-SP ADR (RDHL)

US7574682024 - ADR

0.45  +0.03 (+7.14%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

REDHILL BIOPHARMA LTD-SP ADR

NASDAQ:RDHL (4/19/2024, 2:04:49 PM)

0.45

+0.03 (+7.14%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap13.37M
Shares
PE0.56
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RDHL Daily chart

Company Profile

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Company Info

REDHILL BIOPHARMA LTD-SP ADR

21 Ha'arba'a St.

TEL AVIV-YAFO 64739

P: 97235413131

CEO: Dror Ben-Asher

Employees: 113

Website: https://www.redhillbio.com/

RDHL News

News Image11 days ago - RedHill Biopharma Ltd.RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a...

News Image17 days ago - RedHill Biopharma Ltd.RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...

News Imagea month ago - RedHill Biopharma Ltd.RedHill Announces New USPTO Patent Covering Talicia® Through 2034

U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia...

News Image2 months ago - RedHill Biopharma Ltd.RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by...

News Image2 months ago - Seeking AlphaRedHill Biopharma files to sell 10.6M ADS for holders (NASDAQ:RDHL)

Read about RedHill Biopharma's filing of a prospectus for the resale of 10.6M ADSs, representing 400 shares each, by selling stockholders.

News Image3 months ago - RedHill Biopharma Ltd.RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...

RDHL Twits

Here you can normally see the latest stock twits on RDHL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example